During the recent session, Sutro Biopharma Inc (NASDAQ:STRO)’s traded shares were 0.43 million, with the beta value of the company hitting 1.17. At the last check today, the stock’s price was $3.62, reflecting an intraday gain of 11.38% or $0.37. The 52-week high for the STRO share is $6.13, that puts it down -69.34 from that peak though still a striking 44.48% gain since the share price plummeted to a 52-week low of $2.01. The company’s market capitalization is $296.71M, and the average intraday trading volume over the past 10 days was 0.4 million shares, and the average trade volume was 589.12K shares over the past three months.
Sutro Biopharma Inc (STRO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.18. STRO has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.73.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sutro Biopharma Inc (NASDAQ:STRO) trade information
Sutro Biopharma Inc (STRO) registered a 11.38% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 11.38% in intraday trading to $3.62, hitting a weekly high. The stock’s 5-day price performance is 4.93%, and it has moved by 2.55% in 30 days. Based on these gigs, the overall price performance for the year is 40.31%. The short interest in Sutro Biopharma Inc (NASDAQ:STRO) is 2.86 million shares and it means that shorts have 4.38 day(s) to cover.
The consensus price target of analysts on Wall Street is $11, which implies an increase of 67.09% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $15 respectively. As a result, STRO is trading at a discount of -314.36% off the target high and -120.99% off the low.
Sutro Biopharma Inc (STRO) estimates and forecasts
Statistics show that Sutro Biopharma Inc has underperformed its competitors in share price, compared to the industry in which it operates. Sutro Biopharma Inc (STRO) shares have gone down -5.48% during the last six months, with a year-to-date growth rate less than the industry average at -54.97% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 9.90% this quarter and then drop -242.30% in the quarter after that. In the rating firms’ projections, revenue will decrease -57.00% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 15.25M as predicted by 11 analyst(s). Meanwhile, a consensus of 11 analyst(s) estimates revenue growth to 16.08M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.96%. While earnings are projected to return -66.03% in 2024.
STRO Dividends
Sutro Biopharma Inc is due to release its next quarterly earnings on 2024-Nov-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sutro Biopharma Inc (NASDAQ:STRO)’s Major holders
Sutro Biopharma Inc insiders own 0.96% of total outstanding shares while institutional holders control 78.16%, with the float percentage being 78.91%. BLACKROCK INC. is the largest shareholder of the company, while 171.0 institutions own stock in it. As of 2024-06-30, the company held over 6.91 million shares (or 11.2447% of all shares), a total value of $20.25 million in shares.
The next largest institutional holding, with 7.71 million shares, is of SUVRETTA CAPITAL MANAGEMENT, LLC’s that is approximately 9.4906% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.59 million.
